Last mentioned: Mar 21, 2026
Full Enforcement
Deadline for all UK educational institutions to meet the new statutory requirements.
Mandate Announcement
Government confirms that stocking and training will become compulsory for all schools.
Initial Regulation Change
UK law amended to allow schools to purchase AAIs without a prescription on a voluntary basis.
Invenomic Capital Management has fully liquidated its $24.3 million stake in Haemonetics Corporation (HAE) following a period of significant market underperformance. The move signals a strategic shift for the fund as it reallocates capital toward more resilient healthcare and technology holdings.
Invenomic Capital Management has fully liquidated its $24.29 million position in Haemonetics Corporation, signaling a shift away from the underperforming medical device maker. The exit comes as Haemonetics shares have lagged the broader market, dropping 9% over the past year while the fund rotates capital into diversified healthcare and technology plays.
Invenomic Capital Management has fully liquidated its $24.29 million position in Haemonetics Corporation, a leader in blood and plasma management technology. The exit comes as the stock underperformed the broader market by 25% over the past year, signaling a shift in institutional sentiment toward the medical device sector.
The United Kingdom government has announced a landmark regulatory shift requiring all schools to maintain emergency stocks of adrenaline auto-injectors (AAIs) and provide mandatory staff training. Effective September 2026, the policy transitions allergy preparedness from a discretionary recommendation to a statutory requirement for educational institutions.
A diverse group of industry leaders, including search giant Elastic and consulting firm CRA International, are set to report Q4 results on February 26. The upcoming disclosures will provide critical insights into enterprise AI adoption and the health of professional services in a shifting macroeconomic environment.
A diverse group of mid-to-large cap companies across consumer staples, healthcare, and tech are set to report Q4 results tomorrow. Investors are looking for signs of margin expansion amid stabilizing inflation and the impact of generative AI on software demand.
Viatris (VTRS) and CRA International (CRAI) are scheduled to report Q4 results on February 26, 2026, providing critical insights into the generic drug market and life sciences consulting demand. These reports come as the industry faces significant regulatory and pricing headwinds from the Inflation Reduction Act and a shifting biosimilar landscape.
A diverse group of companies, including J.M. Smucker and Xponential Fitness, are set to report Q4 earnings on February 26, 2026. These reports will provide critical insights into consumer spending patterns across staples, boutique fitness, and enterprise search technology.
Viatris and CRA International are scheduled to report Q4 results tomorrow, providing critical insights into the generic pharmaceutical landscape and life sciences consulting demand. These reports come as the industry grapples with pricing pressures, regulatory shifts, and a stabilizing post-pandemic consulting market.